A world where quality isn’t luck
We believe the quality of psychedelic practice should not depend on who someone happens to find, follow, or be referred to.
About PsyStandard
Get early access
The quality of psychedelic practice shouldn't be a matter of luck
We are building the field infrastructure that turns isolated excellence into transparent, verifiable standards for psychedelic practice across Europe.
Built with the field
Co-designed with experts across research, harm reduction, and clinical and non-clinical practice
Why PsyStandard exists
PsyStandard was created to make excellent psychedelic practice easier to recognise, assess, and trust — for people seeking support, responsible providers, and the wider field.
Field infrastructure for transparent standards
Our vision is to become the European infrastructure that transforms isolated excellence into transparent, verifiable standards for psychedelic practice.
A living verification framework
We co-create a theoretical and practical verification framework with academic institutions, organisations, and practitioners — then make verification transparent and accessible through a public directory.
What we are building
A living standard for psychedelic practice
Excellent psychedelic practice is complex. It involves ethics, competence, safety, setting, preparation, integration, legal context, and the ability to work responsibly with real people in vulnerable moments.
PsyStandard turns that complexity into a living verification framework — designed with the field, tested in practice, and made visible through provider profiles.
Explore verification framework
Co-created with the field
Built with academic institutions, organisations, practitioners, retreats, and clinics who understand the reality of psychedelic work.
Theoretical and practical
Designed to reflect both research-informed principles and what excellent practice actually requires in real-world settings.
Transparent by design
Verification is made visible through a public directory, so people can understand what has been assessed before they contact a provider.
Living, not static
The framework evolves as evidence, regulation, practice, and community feedback evolve.
Core values
The principles we build by
PsyStandard is not only a directory. It is a living standard shaped by responsibility to people, providers, and the psychedelic field itself.
Reduce harm
Every decision runs through one filter first: would we send someone we love here? Verification is not a badge. It is a responsibility.
Startup urgency, institutional endurance
We move fast because the field needs this now. But we do not dilute the standard for speed, volume, or commercial convenience. A standard is only worth something if it holds.
In service to people
Every standard we set, every badge we issue, and every difficult call we make exists for one reason: the person seeking support deserves the best possible care — not by chance, but by design.
We learn with and from each other
The standard is built together. We co-create our frameworks with the organisations, practitioners, retreats, and clinics who live this work every day.
Ethical and excellent
A practitioner can be deeply ethical and still not be good at what they do. We believe psychedelic practice must be both ethically grounded and genuinely competent.
The standard starts with us
We do not just write about standards; we practise them internally. We model integrity in how we build, verify, and show up for the community we serve.
The community practises the standard
PsyStandard is a living ecosystem. The standard gets stronger every time it is used, challenged, and refined by practitioners, retreats, clinics, organisations, and people seeking support.
Pink Elephant Group
We are part of the Pink Elephant Group, building field infrastructure for psychedelic practice in Europe.
TEAM
The team behind PsyStandard
We built PsyStandard because we've seen what happens when the field lacks infrastructure.
Sophie comes from a business background and about three years ago, following a personal experience, shifted her life’s focus to what matters most to her — enabling broad access to safe psychedelic experiences. She founded a boutique psychedelic experience company and is currently training as a psychedelic practitioner herself. At PsyStandard she and Max are jointly responsible for the organisation's strategic direction and standards.
Max has worked in the psychedelic industry for over six years, across business development, fundraising, and communications — long enough to watch the field's credibility problem outpace its growth. At PsyStandard he and Sophie are jointly responsible for the organisation's strategic direction and standards.
Laurin contributes as a neuroscience and strategy advisor and psychedelic practitioner. His work connects PsyStandard’s verification and quality framework with practitioner realities, neuroscience-informed thinking, and the wider community for practitioners and the psychedelic-curious.
Tanya is a psychologist who came to psychedelic work two years ago, drawn by the gap between how much these experiences can matter to people and how little structure exists to protect them. At PsyStandard she builds and manages the relationships with practitioners — the working partnerships that verification depends on.
Ivan works on the product experience across PsyStandard and States of Mind. He focuses on turning the verification framework and provider directory into a usable marketplace experience for people seeking psychedelic support and for providers joining the ecosystem.
GZ psychologist, psychotherapist, and entrepreneur with 35+ years of experience in mental health care. Founder and director of 1nP (2003–2025), the first financially sustainable network organization for mental health professionals, built through innovative workflows and digitalization. Passionate about psychedelic therapy and systems-oriented care innovation.
Neuropsychopharmacologist and UKRI Postdoctoral Fellow at the Centre for Psychedelic Research and Neuropsychopharmacology, Imperial College London, and a Senior Researcher at Drug Science. Working alongside Professor David Nutt, his research focuses on the neurobiology of addiction and mental health disorders, with a particular interest in how psychedelic compounds (including psilocybin, DMT and LSD), ketamine, MDMA and cannabis affect the brain and may be used as treatments for addiction.
